Burden and cost of treatment for GERD
- 1 November 2005
- journal article
- Published by Springer Science and Business Media LLC in The Esophagus
- Vol. 40 (11), 1083-1084
- https://doi.org/10.1007/s00535-005-1701-1
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- “Proton-pump inhibitor-first” strategy versus “step-up” strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in JapanThe Esophagus, 2005
- Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non‐erosive gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 2005
- Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonistsAlimentary Pharmacology & Therapeutics, 2004
- The burden of illness of gastro‐oesophageal reflux disease: impact on work productivityAlimentary Pharmacology & Therapeutics, 2003
- Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a Health Maintenance OrganizationThe American Journal of Gastroenterology, 2000
- Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?The Esophagus, 1999
- Helicobacter pylori independent chronological change in gastric acid secretion in the JapaneseGut, 1997